Navigation Links
Halozyme To Present New Data On PEGPH20 In Pancreatic Cancer At American Society of Clinical Oncology Annual Meeting
Date:5/15/2013

Halozyme. "We look forward to the study investigators presenting the updated study results at the poster session and ensuing discussion."

Based on the magnitude of response and safety observed in the Phase 1b study, Halozyme announced in April the initiation of a Phase 2 multicenter, randomized clinical trial evaluating PEGPH20 as a first-line therapy for patients with stage IV metastatic pancreatic cancer. Approximately 124 patients will participate in the study and receive gemcitabine and nab-paclitaxel either with or without PEGPH20. Secondary endpoints of the trial include clinical evaluation of patient response in both treatment arms by tumor biopsy hyaluronan (HA) status.

Halozyme is also developing a HA diagnostic tool that will help evaluate potential treatment benefit based on HA levels for use in the randomized Phase 2 trial. Clinically validating this HA-diagnostic approach in the pancreatic cancer trial may also provide proof-of-concept for use of PEGPH20 in other HA-rich tumor types.

Halozyme Abstracts at ASCO:

  • Poster Presentation/Discussion: (E Hall D1): "A Phase 1b Study of Gemcitabine Plus PEGPH20 (PEGylated Recombinant Human Hyaluronidase) in Patients with Stage IV Previously Untreated Pancreatic Cancer" will be presented by Sunil R. Hingorani M.D ., Ph.D., Fred Hutchinson Cancer Research Center on Monday, June 3 at 1:15PM-5:15PM CDT; discussion from 4:45 PM-5:45PM CDT. (Abstract #4010)
  • Educational Book Abstract: "Pharmacokinetic (PK)/Pharmacodynamic (PD) Results From a Phase 1b Study of PEGylated Hyaluronidase PH20 (PEGPH20) in Combination with Gemcitabine (Gem) in Patients with Pancreatic Cancer" (Abstract # e15005)

*33 percent response rate reported in the ASCO abstract based on partial data available at the time of abstract submission.

About Pancreatic Cancer
In most patients diagnosed with metastat
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Halozyme Therapeutics to Present at the 30th Annual J.P. Morgan Healthcare Conference
2. Halozyme to Host Fourth Quarter and 2011 Year-End Financial Results Conference Call
3. Halozyme Therapeutics to Present at Two Upcoming Investor Conferences in March
4. Halozyme to Host Second Quarter Financial Results Conference Call
5. Halozyme to Host Fourth Quarter and 2012 Year-End Financial Results Conference Call
6. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
7. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
8. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
9. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
10. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
11. Masimo to Present at 23rd Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... SANTA BARBARA, CALIFORNIA (PRWEB) April 28, 2015 ... regulatory consulting firm in the life sciences industry, is ... Validate Salesforce and Move Your GxP Processes to ... sciences organizations are realizing the huge potential and power ... some life sciences organizations worry that data in a ...
(Date:4/28/2015)...  Adaptive Biotechnologies today announced the recent publication ... University of Texas MD Anderson Cancer Center showing ... and quantification of populations of B cells can ... people with classical Hodgkin,s lymphoma (CHL). The findings, ... , represent a first step toward developing a ...
(Date:4/28/2015)... Mass. (PRWEB) April 28, 2015 ... outsourced medical device manufacturing services for complex ... , today announced plans to develop a new ... Conn. , CIRTEC has a long history ... innovative startups to usher breakthrough neurostimulation, heart assistance, ...
(Date:4/28/2015)... , and ANN ARBOR, Mich. , ... cohort published OncoTargets and Therapy today shows ... than Foundation Medicine,s FoundationOne test across a number of ... actionable biomarker targets. The purpose of the ... available NGS platforms for profiling cancer patients compared with ...
Breaking Biology Technology:USDM Life Sciences Partners with Salesforce.com for Webinar on How Life Sciences Organizations Can Move GxP Processes to the Cloud 2Adaptive Biotechnologies and Researchers from MD Anderson Cancer Center Demonstrate Ability to Detect Hodgkin's Lymphoma in Blood 2Adaptive Biotechnologies and Researchers from MD Anderson Cancer Center Demonstrate Ability to Detect Hodgkin's Lymphoma in Blood 3CIRTEC Medical Systems Expands Capacity with New Advanced Manufacturing Facility 2Paradigm Cancer Diagnostic Test (PCDx) Performed Better Than FoundationOne In Side by Side Clinical Study 2Paradigm Cancer Diagnostic Test (PCDx) Performed Better Than FoundationOne In Side by Side Clinical Study 3
... COLUMBIA, Md., Sept. 2 ACell, Inc. is announcing ... , , The conference will be held ... Palace Hotel in New York City. James DeFrancesco, Chief Executive Officer ... 11th beginning at 9:10 AM (EDT) in the Hubbard Room. The ...
... HAYWARD, Calif., Sept. 2 Advanced Cell Diagnostics, Inc. ... of its Series A equity financing from Morningside Ventures, bringing ... , , ACD will use the funds ... on the company,s patent pending RNAscope(TM) technology. "This second closing ...
... , , INDIANAPOLIS, Sept. 2 ... announced that, effective October 1, 2009, it would increase the ... kg for all non-contract customers or as existing contracts permit. ... invest in expanding global supply for the high performance, reducing ...
Cached Biology Technology:ACell's CEO to Present at Rodman & Renshaw's 2009 Annual Global Investment Conference 2ACD Completes the Second Closing of Series A Financing and Initiates Services for Biomarker Validation and Companion Diagnostic Development 2
(Date:4/20/2015)... PASADENA, Calif. , April 20, 2015 ... San Gabriel Valley to implant a new miniaturized, wireless ... HF System is the first and only FDA-approved heart ... reduce hospital admissions when used by physicians to manage ... a sensor that is implanted in the pulmonary artery ...
(Date:4/17/2015)... , April 17, 2015 ... concerns, and technological advancement to drive biometric systems ... until 2020   According to a ... Biometric Systems Market Forecast &  Opportunities, 2020 ", biometric systems market in ... to register growth at CAGR of over 22% ...
(Date:4/14/2015)... 14, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market, announces that ... 2015 New York Design Awards under the category  ,Product ... City Design Awards are part of a global multi-disciplinary ... ratings from the marketplace, industry and judging panel. Winners ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
... 6, 2013) -- Researchers at Weill Cornell Medical College have ... circuits in a developing brain -- gaining unprecedented insight into ... from autism to mental retardation. In the journal ... faulty wiring occurs when RNA molecules embedded in a growing ...
... of treatment for patients with end-stage liver disease, the 12th ... research from the Icahn School of Medicine at Mount Sinai, ... today, suggests that it may one day become possible to ... disease. Investigators discovered that a human embryonic stem cell can ...
... of vitamin D are associated with high levels of hepatitis ... , a journal of the American Association for the Study ... HBV levels point to a link in these variables among ... are available, HBV still remains one of the most significant ...
Cached Biology News:Researchers discover how brain circuits can become miswired during development 2Researchers discover how brain circuits can become miswired during development 3Mount Sinai discovers new liver cell for cellular therapy to aid in liver regeneration 2Vitamin D deficiency may help spread of hepatitis B throughout liver 2
... mir Vana miRNA Bioarray Essentials Kit provides ... and post-hybridization washing of the mir Vana ... has been labeled using Ambions mir Vana ... positive control miRNA (Bioarray ID BA10001) that should ...
... Intracellular Localization Kit provides a straight forward ... of your design, in an efficient yet ... Subcellular localization and functional inhibition of target ... of the labeled siRNA into mammalian cells. ...
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. ID clarifier: box ...
... The InnoCyte Laminin-Based 96-well Cell Invasion Assay ... of cells using laminin as a significant ... anti-metastatic agents in vitro in a convenient, ... size is appropriate for all types of ...
Biology Products: